Abstracts tagged "autoantibodies"

Abstract Number: 2862 • 2013 ACR/ARHP Annual Meeting
Autoantigen Microarray Analysis Of Sera From New-Onset Pediatric Systemic Lupus Erythematosus Patients: A Distinct Autoantibody Profile Associated With Class III/IV Lupus Nephritis
Imelda Balboni¹, David Haddon², Vivian Diep², Cindy Limb² and Paul Utz², ¹Pediatrics, Stanford University School of Medicine, Palo Alto, CA, ²Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease characterized by the production of autoantibodies directed against highly-conserved nuclear antigens. 15-20% of SLE…
Abstract Number: 1890 • 2013 ACR/ARHP Annual Meeting
Chemokine Receptor Polymorphisms On Chromosome 3 Are Associated With Anticitrullinated Protein Antibody Specificities In African Americans With Rheumatoid Arthritis
Richard J. Reynolds¹, Maria I. Danila², Jeremy Sokolove³, William H. Robinson⁴, Doyt L. Conn⁵, Beth L. Jonas⁶, Leigh F. Callahan⁷, Larry W. Moreland⁸, Richard D. Brasington⁹, Edwin A. Smith¹⁰, Peter K. Gregersen¹¹ and S. Louis Bridges Jr.¹², ¹Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Med/Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ³VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁴Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁵Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ⁶Thurston Arthritis Research Ct, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Div of Rheumatology, Washington Univ School of Med, St. Louis, MO, ¹⁰Dept of Med Div of Rheum, Med Univ of South Carolina, Charleston, SC, ¹¹Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ¹²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: ACPA antibody specificities to citrullinated autoantigens (e.g., histones, vimentin, fibrinogen) are associated with the preclinical phase of RA and may predict the onset of…
Abstract Number: 921 • 2013 ACR/ARHP Annual Meeting
Blocking The Complement Receptor 2 (CR2) Ligand-Receptor Interaction With a Novel Mouse Anti-Mouse CR2 Monoclonal Antibody Decreases Antigen-Specific Humoral Immune Responses and The Evolution Of Collagen-Induced Arthritis
Rosa Rodriguez¹, Liudmila Kulik¹, Joshua Thurman², Jonathan Hannan¹, Steve Tomlinson³ and V. Michael Holers¹, ¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ²Renal Division, University of Colorado School of Medicine, Aurora, CO, ³Microbiology and Immunology, Medical University of South Carolina, Charleston, NC
Background/Purpose: The CR2/CD19 complex on B cells serves as a co-receptor for membrane IgM and amplifies B cell responses through physical associations of the bound…
Abstract Number: 2713 • 2013 ACR/ARHP Annual Meeting
IL-21 Inhibited Follicular Regulatory T Cells To Promote Autoreactive Germinal Center Development In Autoimmune BXD2 Mice
Yanna Ding¹, Hui-Chen Hsu^2,3, Jun Li⁴, PingAr Yang⁴, Qi Wu⁴, Allan J. Zajac⁵ and John D. Mountz^3,6, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Birmingham VA Medical Center, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Microbiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Follicular T helper (Tfh) cells have been correlated with germinal center (GC) formation, autoantibody production and disease severity in human systemic lupus erythematosus (SLE).…
Abstract Number: 1884 • 2013 ACR/ARHP Annual Meeting
Autoantibody Specificities and Type I Interferon Pathway Activation In Idiopathic Inflammatory Myopathies
Saskia Vosslamber¹, Louise Ekholm², Anna Tjarnlund³, T.D. de Jong¹, Lenka Plestilova⁴, Martin Klein⁵, Peter J. Charles⁶, A.E. Voskuyl⁷, Irene Bultink⁸, Michiel Pegtel¹, J Vencovsky⁹, Ingrid E. Lundberg¹⁰ and Cornelis L. Verweij¹¹, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Pathology, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Clinical and Experimental Rheumatology, Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Prague, Czech Republic, ⁶Oxford University, Kennedy Institute of Rheumatology, Oxford, United Kingdom, ⁷Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁸Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁹Institute of Rheumatology, Prague, Czech Republic, ¹⁰Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ¹¹Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare autoimmune diseases characterized by proximal muscle weakness and muscle inflammation. IIM are associated with several autoantibodies, which are…
Abstract Number: 922 • 2013 ACR/ARHP Annual Meeting
Role Of B Cells and/Or Autoantibodies In Pulmonary Manifestations Of Inflammatory Arthritis
Lisa K. Peterson¹, Jeremy Sokolove², Paul Jedlicka³, Lauren J. Lahey⁴, William H. Robinson⁵ and Leonard L. Dragone⁶, ¹Pediatrics, National Jewish Health, Denver, CO, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³Pathology, University of Colorado Denver, Aurora, CO, ⁴Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁵VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁶Dept of Pediatrics, National Jewish Health, Denver, CO
Background/Purpose: RA is a systemic condition affecting approximately 1% of the general population leading to progressive arthritis and extra-articular manifestations (ExRA), including interstitial lung disease…
Abstract Number: 2685 • 2013 ACR/ARHP Annual Meeting
Anti-Peptidylarginine Deiminase 3/4 Cross-Reactive Antibodies Are Associated With Radiographic Interstitial Lung Disease In Rheumatoid Arthritis, An Effect Potentiated By Smoking
Jon T. Giles¹, Erika Darrah², Sonye K. Danoff³, Cheilonda Johnson⁴, Felipe Andrade⁵, Antony Rosen² and Joan M. Bathon⁶, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, ⁴Medicine/Pulmonology, Johns Hopkins University, Baltimore, MD, ⁵Division of Rheumatology, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Columbia University, New York, NY
Background/Purpose: Antibodies targeting citrullinated proteins (ACPA) are implicated in the pathogenesis of interstitial lung disease (ILD) in rheumatoid arthritis (RA). Citrullinated proteins and the enzymes…
Abstract Number: 1844 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Sjogren’s Syndrome and Systemic Lupus Erythematosus Patients Have a Distinct Spectrum Of Serum Anticytokine Autoantibodies
Sarthak Gupta^1,2, Ioanna P. Tatouli³, Lindsey B. Rosen², Sarfaraz A. Hasni¹, Richard M. Siegel¹, Steven M. Holland², Haralampos M. Moutsopopoulos³ and Sarah K. Browne², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, the prevalence and significance of anticytokine autoantibodies in rheumatic conditions is poorly…
Abstract Number: 923 • 2013 ACR/ARHP Annual Meeting
Redox Dependent Conformational Changes Of The Autoantigen La Are Responsible For Its Shuttling, Translocation and a Pathophysiological Role Of Anti-La Autoantibodies
Irene Michalk¹, Nicole Berndt¹, Claudia C. Bippes¹, Holger Bartsch², Stefanie Koristka³, Claudia Arndt¹, Anja Feldmann¹, Biji T. Kurien⁴, Robert Hal Scofield⁵, A. Darise Farris⁶, Judith A. James⁷, Marc Cartellieri¹ and Michael Bachmann¹, ¹Inst. Immunology, Carl Gustav Carus TU-Dresden, Dresden, Germany, ²Inst. Immunol., Carl Gustav Carus TU-Dresden, Dresden, Germany, ³Carl Gustav Carus TU-Dresden, Dresden, Germany, ⁴College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁶Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Since their detection a pathophysiological role of antibodies (abs) to extractable nuclear autoantigens including anti-La abs has been controversially discussed. Stainings of anti-La abs…
Abstract Number: 2655 • 2013 ACR/ARHP Annual Meeting
Therapeutic Effect Of β2GPI and Its Synthetic derivative Loaded Tolerogenic Dendritic Cells In Experimental Antiphospholipid Syndrome, Is Associated With miRNA 23b, 142-3p and 221 Expression and Tregs Upregulation
Miri Blank¹, Silvia S. Pierangeli², Honorio Torres-Aguilar³ and Yehuda Shoenfeld⁴, ¹Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Sackler Medical School, Tel Aviv University, Ramat Gan, Israel, ²Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ³National Center for Blood Transfusion, Mexico City, Mexico, ⁴Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel
Background/Purpose: The importance of beta-glycoprotein I (beta2GPI)-specific CD4+ T cells in the development of pathogenic processes in patients with antiphospholipid syndrome (APS) and APS mice…
Abstract Number: 1777 • 2013 ACR/ARHP Annual Meeting
Antibodies Against TIF1-Gamma In Cancer Associated Myositis May Precede Cancer Symptoms and Persist After Cancer Removal
Ingrid E. Lundberg¹, Lara Dani², Maryam Dastmalchi², Maria Angeles Martinez³, Moises Labrador-Horrillo⁴ and Albert Selva O'Callaghan⁴, ¹Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Sant Pau Hospital, Barcelona, Spain, ⁴Vall d'Hebron General Hospital, Barcelona, Spain
Background/Purpose: Antibodies against TIF1-gamma have been detected in patients with cancer associated myositis (CAM) but it is not known whether the antibodies precede the diagnosis…
Abstract Number: 926 • 2013 ACR/ARHP Annual Meeting
Autoantibodies to the Th/To Complex Are the Most Common Antibodies in Systemic Sclerosis (SSc) Patients Without Other Autoantibodies
Michael Mahler¹, Jason Y.F. Chan², Edward K.L. Chan³, Minoru Satoh², Marie Hudson⁴, Murray Baron⁵, James Wick⁶ and Marvin J. Fritzler⁷, ¹Research, INOVA Diagnostics, San Diego, CA, ²Medicine, University of Florida, Gainesville, FL, ³Oral Biology, University of Florida, Gainesville, FL, ⁴Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁵Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁶Department of medicine, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Antinuclear antibodies (ANA) play an important role in the diagnosis of systemic sclerosis (SSc) being present in about 80-90% of the patients. In the…
Abstract Number: 2660 • 2013 ACR/ARHP Annual Meeting
Omega-3 Supplement Use Is Associated With a Reduced Risk Of Anti-Cyclic Citrullinated Protein Positivity In a Population Without Rheumatoid Arthritis, But At Risk For Future Disease
Ryan W. Gan¹, Kendra A. Young¹, Gary O. Zerbe², M. Kristen Demoruelle³, Michael H. Weisman⁴, Jane H. Buckner⁵, Peter K. Gregersen⁶, Ted R. Mikuls⁷, James R. O'Dell⁸, Richard M. Keating⁹, Michael J. Clare-Salzler¹⁰, Kevin D. Deane³, V. Michael Holers¹¹ and Jill M. Norris¹, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Biostatistics and Informatics, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁹Rheumatology Section, The University of Chicago, Chicago, IL, ¹⁰Experimental Pathology, University of Florida, College of Medicine, Gainesville, FL, ¹¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is characterized by systemic inflammation and circulating autoantibodies, which can be present in serum years prior to RA diagnosis and can…
Abstract Number: 1786 • 2013 ACR/ARHP Annual Meeting
91% Of Early RA Patients Are Positive For Serum 14-3-3η Or Its Auto-Antibodies
Walter P. Maksymowych¹, Dirkjan van Schaardenburg², Désirée van der Heijde³, Robert Landewé⁴, Gilles Boire⁵, Maarten Boers⁶, Vivian P. Bykerk⁷, Edward C. Keystone⁸, Katherine A. Siminovitch⁹, Mairead Murphy¹⁰ and Anthony Marotta¹¹, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Jan van Breemen Research Institute | Reade, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Int Med/Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁷Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁸Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Augurex Life Sciences Corp., North Vancouver, BC, Canada, ¹¹Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: Current serological markers such as RF and ACPA are useful for early diagnosis and perhaps for screening people at risk, but there remains a…
Abstract Number: 873 • 2013 ACR/ARHP Annual Meeting
Health Fair Evaluations To Identify Subjects At-Risk For Future Inflammatory Arthritis and Rheumatoid Arthritis
Kristen E. Beck¹, M. Kristen Demoruelle², Christopher C. Striebich³, Kaylynn Aiona⁴, Marie L. Feser², Lezlie A. Derber⁵, Stacey Brake⁶, Jill Lysengen⁷, Laura Rosseisen⁷, Julia J. Rhiannon⁸, Stuart M. Weisman⁵, Jill M. Norris⁹, V. Michael Holers¹⁰ and Kevin D. Deane², ¹University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³University of Colorado Denver, Aurora, CO, ⁴Colorado School of Public Health, Aurora, CO, ⁵University of Colorado School of Medicine, Division of Rheumatology, Aurora, CO, ⁶9Health Fair, Denver, CO, ⁷Arthritis Foundation, Great West Region, Denver Office, Denver, CO, ⁸Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁹Epidemiology, Colorado School of Public Health, Aurora, CO, ¹⁰Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Multiple studies demonstrate that there is a preclinical period of rheumatoid arthritis (RA) when autoantibodies (Abs) including RF and anti-CCP are abnormal in absence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].